68Ga-grazytracer PET/CT Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer: a Prospective, Observational Study.
Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which does not meet clinical needs. 68Ga-grazytracer is a novel imaging agent targeting granzyme B. By detecting the concentration of granzyme B, it reflects the localization of cytotoxic T cells in the tumor region and their potential ability to kill tumor cells. This study aims to leverage the simplicity, non-invasiveness, visualization, and semi-quantitative advantages of 68Ga-grazytracer PET imaging to evaluate its effectiveness and feasibility in diagnosing pseudoprogression.
• Lung cancer patients who develope lesion enlargement and/or new lesions after treatment with immune checkpoint inhibitors;
• Pseudoprogression cannot be ruled out in clinical practice;
• Lung cancer confirmed by pathology or cytology, regardless of pathological type;
• Fully-informed written consent obtained from patients;
• Patient ability to comply with protocol requirements;
• Age 18-75 years;
• Life expectancy of at least 6 months.